Business

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials for the Combination of ZG006 for Injection with PD-1/PD-L1 Immune Checkpoint Inhibitor

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials for the Combination of ZG006 for Injection with PD-1/PD-L1 Immune Checkpoint Inhibitor

articleSuzhou Zelgen Biopharmaceuticals Co. Ltd. Class AApril 20, 20254/news/announcement-on-voluntary-disclosure-of-obtaining-notice-of-approval-for-drug-clinical-trials-for-the-combination-of-zg006-for-injection-with-pd-1pd-l1-immune-checkpoint-inhibitor
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials for the Combination of ZG006 for Injection with PD-1/PD-L1 Immune Checkpoint Inhibitor

About this update from Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials for the Combination of ZG006 for Injection with PD-1/PD-L1 Immune Checkpoint InhibitorThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A